Pilot study of antithymocyte globulin in systemic sclerosis

Eric Lawrence Matteson, Mohammad I. Shbeeb, Tim G. McCarthy, Kenneth T. Calamia, Lester E. Mertz, Jörg J. Goronzy

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. Between June 1, 1992 and August 31, 1994 we conducted an open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in 10 patients with early systemic sclerosis (SSc) to assess whether this agent might prevent the progression of cutaneous and pulmonary involvement in this disease. Methods. Adult patients with early SSc (<3 years) and evidence of progressive skin and pulmonary disease were enrolled. All patients were hospitalized and received a single course of intravenous ATGAM, at a dosage of 10 mg/kg over 4 hours, on 5 consecutive days. Patients were followed up at weeks 1, 2, 3, and 4, and months 2, 4, 6, and 12. Patients were considered to be improved if the Rodnan skin score decreased ≤25%, to be worse if the skin score increased ≤25%, and to be not improved if the skin score was within 25% of baseline. For pulmonary involvement, patients were considered to be improved if either the diffusing capacity for carbon monoxide or the forced vital capacity was increased ≤10%, worse if decreased by ≤10%, and stable if within 10% of baseline. Results. Most patients tolerated the treatment well, although 1 patient developed an allergic reaction necessitating discontinuation of treatment, 1 developed a serum sickness reaction after completion of therapy, and I developed a central venous access-related axillary vein thrombosis. Two patients died of SSc-related complications during the followup period. At 12 months, only 2 patients showed improvement in both skin and pulmonary function measures, whereas 5 patients were worse and 3 were stable. Conclusion. At the dosage administered in this study, ATGAM appears ineffective in improving the skin and pulmonary features of SSc.

Original languageEnglish (US)
Pages (from-to)1132-1137
Number of pages6
JournalArthritis and Rheumatism
Volume39
Issue number7
DOIs
StatePublished - Jul 1996

Fingerprint

Antilymphocyte Serum
Systemic Scleroderma
Skin
Lung
Axillary Vein
Serum Sickness
Vital Capacity
Carbon Monoxide
Skin Diseases
Lung Diseases
Hypersensitivity
Thrombosis
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Matteson, E. L., Shbeeb, M. I., McCarthy, T. G., Calamia, K. T., Mertz, L. E., & Goronzy, J. J. (1996). Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis and Rheumatism, 39(7), 1132-1137. https://doi.org/10.1002/art.1780390709

Pilot study of antithymocyte globulin in systemic sclerosis. / Matteson, Eric Lawrence; Shbeeb, Mohammad I.; McCarthy, Tim G.; Calamia, Kenneth T.; Mertz, Lester E.; Goronzy, Jörg J.

In: Arthritis and Rheumatism, Vol. 39, No. 7, 07.1996, p. 1132-1137.

Research output: Contribution to journalArticle

Matteson, EL, Shbeeb, MI, McCarthy, TG, Calamia, KT, Mertz, LE & Goronzy, JJ 1996, 'Pilot study of antithymocyte globulin in systemic sclerosis', Arthritis and Rheumatism, vol. 39, no. 7, pp. 1132-1137. https://doi.org/10.1002/art.1780390709
Matteson EL, Shbeeb MI, McCarthy TG, Calamia KT, Mertz LE, Goronzy JJ. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis and Rheumatism. 1996 Jul;39(7):1132-1137. https://doi.org/10.1002/art.1780390709
Matteson, Eric Lawrence ; Shbeeb, Mohammad I. ; McCarthy, Tim G. ; Calamia, Kenneth T. ; Mertz, Lester E. ; Goronzy, Jörg J. / Pilot study of antithymocyte globulin in systemic sclerosis. In: Arthritis and Rheumatism. 1996 ; Vol. 39, No. 7. pp. 1132-1137.
@article{f004c69699ba4c7ebf4a096291c81afa,
title = "Pilot study of antithymocyte globulin in systemic sclerosis",
abstract = "Objective. Between June 1, 1992 and August 31, 1994 we conducted an open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in 10 patients with early systemic sclerosis (SSc) to assess whether this agent might prevent the progression of cutaneous and pulmonary involvement in this disease. Methods. Adult patients with early SSc (<3 years) and evidence of progressive skin and pulmonary disease were enrolled. All patients were hospitalized and received a single course of intravenous ATGAM, at a dosage of 10 mg/kg over 4 hours, on 5 consecutive days. Patients were followed up at weeks 1, 2, 3, and 4, and months 2, 4, 6, and 12. Patients were considered to be improved if the Rodnan skin score decreased ≤25{\%}, to be worse if the skin score increased ≤25{\%}, and to be not improved if the skin score was within 25{\%} of baseline. For pulmonary involvement, patients were considered to be improved if either the diffusing capacity for carbon monoxide or the forced vital capacity was increased ≤10{\%}, worse if decreased by ≤10{\%}, and stable if within 10{\%} of baseline. Results. Most patients tolerated the treatment well, although 1 patient developed an allergic reaction necessitating discontinuation of treatment, 1 developed a serum sickness reaction after completion of therapy, and I developed a central venous access-related axillary vein thrombosis. Two patients died of SSc-related complications during the followup period. At 12 months, only 2 patients showed improvement in both skin and pulmonary function measures, whereas 5 patients were worse and 3 were stable. Conclusion. At the dosage administered in this study, ATGAM appears ineffective in improving the skin and pulmonary features of SSc.",
author = "Matteson, {Eric Lawrence} and Shbeeb, {Mohammad I.} and McCarthy, {Tim G.} and Calamia, {Kenneth T.} and Mertz, {Lester E.} and Goronzy, {J{\"o}rg J.}",
year = "1996",
month = "7",
doi = "10.1002/art.1780390709",
language = "English (US)",
volume = "39",
pages = "1132--1137",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Pilot study of antithymocyte globulin in systemic sclerosis

AU - Matteson, Eric Lawrence

AU - Shbeeb, Mohammad I.

AU - McCarthy, Tim G.

AU - Calamia, Kenneth T.

AU - Mertz, Lester E.

AU - Goronzy, Jörg J.

PY - 1996/7

Y1 - 1996/7

N2 - Objective. Between June 1, 1992 and August 31, 1994 we conducted an open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in 10 patients with early systemic sclerosis (SSc) to assess whether this agent might prevent the progression of cutaneous and pulmonary involvement in this disease. Methods. Adult patients with early SSc (<3 years) and evidence of progressive skin and pulmonary disease were enrolled. All patients were hospitalized and received a single course of intravenous ATGAM, at a dosage of 10 mg/kg over 4 hours, on 5 consecutive days. Patients were followed up at weeks 1, 2, 3, and 4, and months 2, 4, 6, and 12. Patients were considered to be improved if the Rodnan skin score decreased ≤25%, to be worse if the skin score increased ≤25%, and to be not improved if the skin score was within 25% of baseline. For pulmonary involvement, patients were considered to be improved if either the diffusing capacity for carbon monoxide or the forced vital capacity was increased ≤10%, worse if decreased by ≤10%, and stable if within 10% of baseline. Results. Most patients tolerated the treatment well, although 1 patient developed an allergic reaction necessitating discontinuation of treatment, 1 developed a serum sickness reaction after completion of therapy, and I developed a central venous access-related axillary vein thrombosis. Two patients died of SSc-related complications during the followup period. At 12 months, only 2 patients showed improvement in both skin and pulmonary function measures, whereas 5 patients were worse and 3 were stable. Conclusion. At the dosage administered in this study, ATGAM appears ineffective in improving the skin and pulmonary features of SSc.

AB - Objective. Between June 1, 1992 and August 31, 1994 we conducted an open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in 10 patients with early systemic sclerosis (SSc) to assess whether this agent might prevent the progression of cutaneous and pulmonary involvement in this disease. Methods. Adult patients with early SSc (<3 years) and evidence of progressive skin and pulmonary disease were enrolled. All patients were hospitalized and received a single course of intravenous ATGAM, at a dosage of 10 mg/kg over 4 hours, on 5 consecutive days. Patients were followed up at weeks 1, 2, 3, and 4, and months 2, 4, 6, and 12. Patients were considered to be improved if the Rodnan skin score decreased ≤25%, to be worse if the skin score increased ≤25%, and to be not improved if the skin score was within 25% of baseline. For pulmonary involvement, patients were considered to be improved if either the diffusing capacity for carbon monoxide or the forced vital capacity was increased ≤10%, worse if decreased by ≤10%, and stable if within 10% of baseline. Results. Most patients tolerated the treatment well, although 1 patient developed an allergic reaction necessitating discontinuation of treatment, 1 developed a serum sickness reaction after completion of therapy, and I developed a central venous access-related axillary vein thrombosis. Two patients died of SSc-related complications during the followup period. At 12 months, only 2 patients showed improvement in both skin and pulmonary function measures, whereas 5 patients were worse and 3 were stable. Conclusion. At the dosage administered in this study, ATGAM appears ineffective in improving the skin and pulmonary features of SSc.

UR - http://www.scopus.com/inward/record.url?scp=0029899152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029899152&partnerID=8YFLogxK

U2 - 10.1002/art.1780390709

DO - 10.1002/art.1780390709

M3 - Article

C2 - 8670321

AN - SCOPUS:0029899152

VL - 39

SP - 1132

EP - 1137

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 7

ER -